Write your message
Volume 5, Issue 3 (Summer 2020)                   J Obstet Gynecol Cancer Res 2020, 5(3): 103-109 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Noei Teymoordash S, Arab M, Afsharmoghadam N, Nouri B, Jahed bozorgan T, Talayeh M. A Rare Case of Late Recurrence in Pseudomyxoma Peritonei and Advanced Stage of Borderline Mucinous Ovarian Tumor. J Obstet Gynecol Cancer Res. 2020; 5 (3) :103-109
URL: http://jogcr.com/article-1-292-en.html
1- Fellowship of Gyneco-oncology, Department of Gynecology Oncology, Imam Hossein Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2- Professor of Gyneco-oncology, Department of Gynecology Oncology, Imam Hossein Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran , drmarab@sbmu.ac.ir
3- Professor of Clinical and Anatomical Pathology, Department of Pathology, Imam Hossein Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4- Assistant Professor of Obstetrics and Gynecology, Department of Obstetrics and Gynecology, Shohada-ye Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5- Department of Obstetrics and Gynecology, Mahdiyeh Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract:   (599 Views)

Pseudomyxoma peritonei (PMP) is characterized by mucinous ascites in the peritoneal cavity and might involve the omentum and peritoneum. The PMPs originating from the ovary are mostly caused by ruptured ovarian mature teratomas and mucinous ovarian carcinomas. The present case is a rare advanced mucinous borderline ovarian tumor and late recurrence in PMP in a 52-year-old menopaused woman. She presented with gradual abdominal enlargement and cystic abdominopelvic lesion with internal septa and ascites. The patient underwent total abdominal hysterectomy, bilateral salpingo-oophorectomy, infracolic omentectomy, lymphadenectomy, and appendectomy. Histopathologic examination revealed mucinous borderline tumors. About 5.5 years after the first surgery, she presented with abdominal bloating and a sonography report of peritoneal seeding in the abdomen and pelvis. Abdominal exploration showed gelatinous-mucinous ascites and disseminated peritoneal carcinomatosis. The final histopathologic evaluation indicated PMP. Although the recurrence of mucinous borderline tumors is in an average of two years, the present case had relapsed after 5.5 years as pseudomyxoma with borderline pathology.

Full-Text [PDF 676 kb]   (331 Downloads) |   |   Full-Text (HTML)  (85 Views)  
Systematic Review: Case Report | Subject: Gynecology Oncology
Received: 2020/10/10 | Accepted: 2020/10/27 | Published: 2020/12/2

1. Baquedano L, Lanzón A, Bolea R, José Y, et al. Pseudomyxoma Peritonei and Ovarian Mucinous Borderline Tumor. Int Gyn & Women's health. 2018; 2(4):184-6 [DOI:10.32474/IGWHC.2018.02.000142]
2. Claes G.Trope, Gunnar Kristensen, Amin makar. Surgery for Borderline Tumor of the Ovary. Seminars in Surgical Oncology. 2000; 19:69-75. https://doi.org/10.1002/1098-2388(200007/08)19:1<69::AID-SSU11>3.0.CO;2-E [DOI:10.1002/1098-2388(200007/08)19:13.0.CO;2-E]
3. Seok Ju Seong1, Da Hee Kim1, Mi Kyoung Kim1et al. Controversies in borderline ovarian tumors. J Gynecol Oncol.2015;26(4):343-349
4. Lalwani N, Shanbhogue AK, Vikram R, et al. Current update on borderline ovarian neoplasms. AJR Am J Roentgenol 2010;194:330-6. [DOI:10.2214/AJR.09.3936] [PMID]
5. Diop AD, Fontarensky M, Montoriol PF, et al. CT imaging of peritoneal carcinomatosis and its mimics. Diagn Interv Imaging. 2014;95:861-72. [DOI:10.1016/j.diii.2014.02.009] [PMID]
6. van Ruth S, Acherman YIZ, van de Vijver MJ et al. Pseudomyxoma peritonei: a review of 62 cases. Eur J Surg Oncol. 2003;29:682-8. [DOI:10.1016/S0748-7983(03)00149-5]
7. Carr NJ, Cecil TD, Mohamed F, et al. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the Peritoneal Surface Oncology Group International (PSOGI) modified Delphi process. Am J Surg Pathol. 2016;40:14-26. [DOI:10.1097/PAS.0000000000000535] [PMID]
8. Smeenk RM, van Velthuysen ML, Verwaal VJ, et al. Appendiceal neoplasms and pseudomyxoma peritonei: a populationbased study. Eur J Surg Oncol. 2008; 34(2): 196-201. [DOI:10.1016/j.ejso.2007.04.002] [PMID]
9. Manmeet Saluja, Diane N. K, John P. K et al. Pseudomyxoma Peritonei arising from a mucinous borderline ovarian tumour: Case report and literature review. ANZJOG. 2010 50(4):399-403
10. Smeenk RM, Bruin SC, van Velthuysen ML, Verwaal VJ. Rosai J. Pseudomyxoma peritonei. Curr Probl Surg. 2008;45:527-75 [DOI:10.1067/j.cpsurg.2008.04.003] [PMID]
11. Hart WR. Borderline epithelial tumors of the ovary. Mod Pathol. 2005;18(1):S33-50
12. Biljana Djordjevic, Simonida Stojanovic, Nadica Ljubenovic et al. Pseudomyxoma peritonei and mucinous ovarian tumors. Acta Medica Medianae. 2008;47:46-49
13. Svintsitskiy V.S, Vorobyova L, Klymenko E.S, Dermenzhy T.V et al. Recurrence of borderline ovarian tumors. Exp Oncol 2013;35(2):118-121.
14. Zaino RJ, Brady MF, Lele SM, Michael H, Greer B and Bookman MA: Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: A Gynecologic Oncology Group study. Cancer.2011;117: 554-562. [DOI:10.1002/cncr.25460] [PMID] [PMCID]
15. Dong Sushi, Yong Song, Byung SU, SUL Lee et al. An unusual case of pseudomyxoma peritonei associated with synchronous primary mucinous tumors of the ovary and appendix: A case report. Oncology Letters.2017;13:4813-4817. [DOI:10.3892/ol.2017.6079] [PMID] [PMCID]
16. Grace Willibell, Deepa Shanmugham. Huge borderline mucinous tumour of ovary- A rare case report. Indian Journal of Obstetrics and Gynecology Research. 2018;5(2):290 - 292 [DOI:10.18231/2394-2754.2018.0063]
17. Cássia Fonseca, Saulo Carvalho,Teresa Cunha et al. The many faces of pseudomyxoma peritonei: a radiological review based on 30 cases. Radiol Bras. 2019;52(6):372-377 [DOI:10.1590/0100-3984.2019.0044] [PMID] [PMCID]
18. Nayyar N, Lakhwani P, Goel A, Pande PK, Kumar K. Management of Borderline Ovarian Tumors-Still a Gray Zone. Indian J Surg Oncol. 2017;8(4):607-614 [DOI:10.1007/s13193-017-0697-3] [PMID] [PMCID]
19. Hiroaki Nagano, Mariko Fujibayashi, Hideomi Sanai et al. A case of mucinous borderline ovarian tumor with microinvasion that relapsed, with an adverse prognosis. Int Canc Conf J. (2012);1:19-23. [DOI:10.1007/s13691-011-0002-1]
20. Rebecca Buell-Gutbrod, and Katja Gwin. Pathologic Diagnosis, Origin, and Natural History of Pseudomyxoma Peritonei. ASCO educational book.2013;221.225
21. Akhavan, Mousavi, Alibakhshi. Diagnosis and Management of Borderline Ovarian Tumor Based on the Iranian Guidelines. J Obstet Gynecol Cancer Res. 2016; 1(1)
22. Prayson RA, Hart WR, Petras RE. Pseudomyxoma peritonei. A clinicopathologic study of 19 cases with emphasis on site of origin and nature of associated ovarian tumors. Am J Surg Pathol. 1994;18(6):591-603.
23. Alejandra AS, Laura SM, Javier DS. Management of borderline ovarian tumours: a comprehensive review of the literature. Ecancermedicalscience. 2014; 8: 403-410.
24. N. Colombo1, C. Sessa, A. du Bois et al. ESMO-ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease. Ann Oncol. (2019); 30: 672-705.
25. Li Sun, Ning Li, Yan Song et al. Clinicopathologic Features and Risk Factors for Recurrence of Mucinous Borderline Ovarian Tumors: A Retrospective Study With Follow-up of More Than 10 Years. Int J Gynecol Cancer. 2018 ;28(9):1643-1649 [DOI:10.1097/IGC.0000000000001362] [PMID]
26. Sugarbaker PH, Dainty LA.Recurrent Mucinous Ovarian Neoplasms: Rationale and Results of a New Treatment Plan in Four Patients. J Cas Rep Stud. 2019;7(2):208 [DOI:10.15744/2348-9820.7.208]

Add your comments about this article : Your username or Email:

Send email to the article author

© 2021 CC BY-NC 4.0 | Journal of Obstetrics, Gynecology and Cancer Research (JOGCR)

Designed & Developed by : Yektaweb | Piblisher: Farname Inc.